【24h】

Radiotherapy in primary cerebral lymphoma

机译:原发性脑淋巴瘤的放射治疗

获取原文
获取原文并翻译 | 示例
           

摘要

Primary cerebral lymphoma is a rare disease with an unfavorable prognosis. Whole brain radiotherapy has been the standard treatment, but neither the optimal radiation fields nor optimal dose level of the regimen are as yet firmly established. From this review of the literature, it seems that the whole brain must be treated, and a boost to the area of the primary site must be discussed. With regard to dose, the radiation dose-response relationship is not clearly proven. Yet, a minimum dose of 40 Gy is necessary, and the maximum dose is set at 50 Gy because of late neurological sequelae. Because of the poor prognosis of this disease and the risk of late sequelaes, other avenues have been explored. Chemotherapy has been studied, seem to have a survival advantage and combinations of radiotherapy and chemotherapy, especially with high-dose methotrexate. Because primary cerebral lymphoma is an uncommon disease, randomized clinical trials that compare radiotherapy alone to chemotherapy plus radiotherapy may not be feasible. Finally, even if chemotherapy seems to have a survival advantage, the regimen of chemotherapy is still a matter of debate.
机译:原发性脑淋巴瘤是一种罕见的疾病,预后不良。全脑放射疗法一直是标准治疗方法,但是尚无确切的方案确定最佳放射线区域或最佳剂量水平。从文献回顾来看,似乎必须对整个大脑进行治疗,并且必须讨论增强原发部位的问题。关于剂量,辐射剂量-反应关系尚未明确证明。然而,由于晚期神经系统后遗症,最小剂量为40 Gy是必要的,最大剂量被设置为50 Gy。由于该疾病的预后较差和存在后遗症的风险,因此已经探索了其他途径。已经对化学疗法进行了研究,似乎具有生存优势,并且放疗和化学疗法相结合,尤其是大剂量甲氨蝶呤。由于原发性脑淋巴瘤是一种罕见的疾病,因此比较单独放疗与化学疗法加放疗的随机临床试验可能不可行。最后,即使化疗似乎具有生存优势,化疗方案仍是一个有争议的问题。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号